That English as a second language is showing through in almost all your posts. You may want either to purchase a book of idiomatic expressions, or to listen more carefully to native English speakers. Do you post from the Philippines or Latin America? Perhaps you are just from there.
I on the other hand am glad MNKD has not moved up so much. Each day it moves down about 1.6% to 2% or more, I buy a few thousand more shares. When I bought earlier this year in the $2 handle range, I did not get a chance to buy as much as I wanted. I am able to buy more a few times a week with the current MNKD price action. I would welcome a big down day, and maybe we get it if the overall market tanks. I have my larger buy orders in just waiting and hoping for some lower level fills.
I found the video from today. If you insert the Bloomberg web address as the prefix the text below will get you to the video. The woman who does the spot shows the inhaler, talks a bit about 30% of diabetics don't do their insulin right because of compliance with needles, shows a world map with growth of diabetes on each continent, etc.
This is a tremendous blog article that was originally written in 2010. Not much has changed with Afrezza except the much smaller, better inhaler plus more rigorous trial data and more advantageous trial data for Afrezza It gives a large number of details about Afrezza trial information as well as advantages of Afrezza. It also gives specific details about Exubera and the reasons for its failure in the market, and why no one should be making comparisons between Afrezza and Exubera. They have totally different chemistries in the body.
Google The Afrezza Paradigm Shift . It was the first link presented on my search.